Combinations of PKC inhibitors and therapeutic agents for treating cancers
AssigneeSloan-Kettering Institute for Cancer Research
InventorsGary K. Schwartz, Anthony P. Albino
Life of this patent
Estimating the term…
Abstract
This invention provides methods for screening a modulating agent which when combined with antitumor therapeutic agent increases apoptosis in tumor cells. This invention also provides methods for screening antitumor therapeutic agents suitable for combination therapy with a protein kinase C inhibitors capable of potentiating apoptosis in tumor cells. This invention further provides different combination therapies comprising the specific protein kinase C inhibitors and the antitumor therapeutic agents.
Claims21
A method for treating cancer in a subject comprising administering sequentially to the subject an amount of antitumor therapeutic agent followed by an amount of a protein kinase C inhibitor, wherein the amounts of antitumor therapeutic agent and protein kinase C inhibitor combined are effective to treat cancer in the subject.
A method for treating cancer in a subject comprising administering sequentially to the subject an amount of an antitumor therapeutic agent followed by an amount of bryostatin-1, wherein the amounts of antitumor agent and bryostatin-1 combined are effective to treat cancer in the subject.
A method for treating cancer in a subject comprising administering sequentially to the subject an amount of paclitaxel followed by an amount of bryostatin-1, wherein the amounts of paclitaxel and bryostatin-1 combined are effective to treat cancer in the subject.
A method for treating esophageal carcinoma in a subject comprising administering sequentially to the subject an amount of paclitaxel followed by an amount of bryostatin-1, wherein the amounts of paclitaxel and bryostatin-1 combined are effective to treat esophageal carcinoma in the subject.
Dependencies are inferred from the claim text.